Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment)- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

The global breast cancer diagnostics market size was estimated at USD 4.49 billion in 2023 and is projected to hit around USD 9.00 billion by 2033, growing at a CAGR of 7.2% during the forecast period from 2024 to 2033.

Breast Cancer Diagnostics Market Size, 2024 to 2033

Key Takeaways:

  • North America dominated the market with a revenue share of 46.00% in terms of revenue in 2023.
  • The imaging segment dominated the overall market with a revenue share of 53.74% in 2023.
  • The blood test segment is anticipated to grow at the fastest growth rate over the forecast period with a CAGR of 9.9%
  • The instrument-based products segment dominated the overall market with a revenue share of 72.18% in 2023.
  • The platform-based products segment is anticipated to grow at a CAGR of 9.3% over the forecast period.
  • The diagnostic & predictive segment dominated the overall market with a revenue share of 49.4% in 2023.
  • The prognostic segment is expected to grow at a CAGR of 8.4% over the forecast period.
  • The hospitals & clinics segment dominated the overall market with a revenue share of 51.00% in 2023.
  • The medical labs & diagnostics centers segment is anticipated to grow at the fastest growth rate over the forecast period with a CAGR of 8.2%.

Breast Cancer Diagnostics Market Size in the U.S. 2023 to 2032

The U.S. Breast Cancer Diagnostics market size was valued at USD 1.51 billion in 2023 and is anticipated to reach around USD 3 billion by 2033, growing at a CAGR of 7.1% from 2024 to 2033.

U.S. Breast Cancer Diagnostics Market Size, 2024 to 2033

North America dominated the market with a revenue share of 46.00% in terms of revenue in 2023. The growth can be attributed to the increasing prevalence of breast cancer and rising government initiatives to increase the screening & diagnostic rate. For instance, according to the American Cancer Society, there were approximately 49,290 breast cancer-related fatalities in the U.S. in 2021, with an expected 281,550 new cases of breast cancer being diagnosed. The U.S. held the largest market share of the market in North America. The growth can be attributed to the increasing prevalence of breast cancer and rising government initiatives aimed at enhancing screening & diagnostic rates in the country. There is a growing demand for technologically advanced products that offer improved accuracy, speed, and cost-effectiveness, which is expected to drive market growth over the forecast period.

Breast Cancer Diagnostics Market  Share, By Region, 2023 (%)

Asia Pacific market is expected to grow at a lucrative rate owing to various factors, such as increasing healthcare reforms, rising incidence of breast cancer, significant R&D investments in breast cancer therapies, and advancements in breast imaging technologies. Breast cancer is the most commonly diagnosed cancer in most Asian countries, with incidence rates rising at a faster rate compared to Western countries due to lifestyle and dietary changes. The CDC highlights breast cancer as a prevalent cancer among women, regardless of ethnicity or race. The rising prevalence of breast cancer, coupled with the development of healthcare infrastructure in Asia Pacific, is expected to drive overall market growth.

Breast Cancer Diagnostics Market Growth

The market is anticipated to witness growth due to the rising incidence of breast cancer, which is recognized as one of the most prevalent cancers worldwide. According to the American Cancer Society, it is estimated that approximately 281,550 new cases of breast cancer will be diagnosed in 2021, with an expected 49,290 related deaths in the U.S. alone. Globally, breast cancer has been identified by the WHO as the most common type of cancer, with new cases surpassing 2.3 million in 2021. These statistics highlight the urgent need for advanced breast cancer diagnostic solutions to facilitate early detection, accurate prognosis, and effective treatment strategies.

Aging is one of the greatest risk factors for breast cancer. With age, the immune system is affected. This increases susceptibility to various diseases. Hence, the geriatric population requires better healthcare services, especially for the treatment/management of chronic conditions such as breast cancer. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed with breast cancer. Breast cancer is the most commonly occurring cancer among women and its prevalence is substantially increasing in developing economies, where the maximum number of cases are being diagnosed at later stages. Even though it is considered to be a disease more widespread in developed economies, about 50% of cases and 58% of deaths due to breast cancer occur in developing countries. This is expected to boost the demand for breast cancer diagnostics in developing economies over the forecast period.

Technological advancements have played a crucial role in enhancing breast cancer diagnostics, enabling earlier detection and more precise treatment strategies. Notable advancements include digital mammography, which utilizes X-rays to create detailed breast images, offering improved image quality and visualization through image manipulation. Another innovation is 3D mammography, also known as digital breast tomosynthesis, which provides a more accurate assessment of breast abnormalities. The growing demand for technologically advanced products is expected to drive market growth, as they offer benefits such as accuracy, speed, and cost-effectiveness. One such area witnessing rapid growth is Direct-to-Consumer (DTC) testing in the market. Companies such as 23andMe recently received U.S. FDA approval for the first DTC test for BRCA gene mutations, which increase the risk of breast and ovarian cancers.

Advancements in minimally invasive procedures have revolutionized breast cancer diagnostics, with techniques such as stereotactic and ultrasound-guided biopsies allowing precise tissue sampling without the need for surgery. These procedures can also be utilized for image-guided tumor ablation, effectively destroying cancer cells while minimizing damage to healthy tissues. The demand for cancer diagnosis tools is increasing worldwide due to technological advancements. Support from regulatory bodies such as the FDA for the development of cancer biomarkers & mass cytometry, the launch of innovative flow cytometry reagents for drug discovery & diagnosis, and the development of technologically advanced miniaturized devices for portability & precision are driving the market growth. Moreover, initiatives to develop novel imaging solutions for more accurate cancer diagnosis are fueling market growth, such as the collaboration between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center to develop radiopharmaceutical products.

Early detection of breast cancer is key to effective management of the disease. It can result in improved quality of life, provide several treatment options, and increase the survival rate. According to a 2021 article published in Research Fast Facts, regular screening and early detection with mammography can decrease breast cancer rates by around 30%. Furthermore, research conducted to develop tests that can detect breast cancer as early as possible is expected to boost market growth. For instance, in November 2019, a study was conducted by researchers at the University of Nottingham to develop a blood test that detects breast cancer 5 years before its occurrence. In this study, screening technology was used to rapidly screen blood samples to determine the presence of antibodies against 40 Tumor-Associated Antigens (TAAs).

Breast Cancer Diagnostics Market Report Scope

Report Attribute Details
Market Size in 2024 USD 4.82 Billion
Market Size by 2033 USD 9.00 Billion
Growth Rate From 2024 to 2033 CAGR of 7.2%
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Type, product, application, end-use, region
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled Hologic Inc.; Genomic Health (Exact Sciences Corporation); BD; Danaher; Koninklijke Philips N.V.; QIAGEN; Thermo Fisher Scientific Inc.; Myriad Genetics, Inc.; Argon Medical Devices, Inc.; F. Hoffmann-La Roche Ltd.

 

Type Insights

On the basis of type, the market is segmented into imaging, biopsy, genomic tests, blood tests, and others. The imaging segment dominated the overall market with a revenue share of 53.74% in 2023. The breast cancer diagnostics market witnessed significant growth in 2022 due to the widespread adoption of imaging techniques like mammography, ultrasound, and MRI. These modalities have become the primary tools for breast cancer diagnosis, while advanced technologies such as MBI, CT, 3D breast tomosynthesis, and PET show great potential for transforming breast imaging capabilities.

In October 2022, the American College of Radiology (ACR), in collaboration with GE Healthcare and the Breast Cancer Research Foundation, launched the Contrast-Enhanced Mammography Imaging Screening Trial (CMIST). This trial aims to evaluate the effectiveness of contrast-enhanced mammography as a screening tool for breast cancer.

The blood test segment is anticipated to grow at the fastest growth rate over the forecast period with a CAGR of 9.9% driven by extensive research studies conducted by research organizations and major players. The high effectiveness of liquid biopsy tests contributes to the growth in the number of blood tests. In April 2023, Syantra achieved CE Mark approval for its breast cancer test, utilizing the Syantra DX Liquid Biopsy Platform, which offers a blood-based method for breast cancer detection. This milestone signifies significant progress in improving diagnostics for breast cancer screening.

Product Insights

On the basis of product, the market is segmented into platform-based products and instruments-based products. The instrument-based products segment dominated the overall market with a revenue share of 72.18% in 2023. It is further segmented into biopsy and imaging. Breast cancer diagnosis heavily relies on widely utilized techniques and products. To raise awareness about breast cancer, promote early detection, and educate people about treatment options, various organizations, including the National Breast Cancer Foundation, are actively undertaking initiatives. Imaging stands as the preferred method for population-based screening of breast cancer patients.

The platform-based products segment is anticipated to grow at a CAGR of 9.3% over the forecast period. Platform-based products are segmented into Next-generation Sequencing (NGS), PCR, microarrays, and others. This segment is anticipated to exhibit a CAGR of 9.3%, owing to wide application in laboratories and is preferred for low false-positive rates. Moreover, these tests are also useful in directing the patients toward a therapy better suited for their genetic makeup and type of disease.

Application Insights

On the basis of application, the market is segmented into screening, diagnostic & predictive, prognostic, and research. The diagnostic & predictive segment dominated the overall market with a revenue share of 49.4% in 2023. The diagnostic stage of breast cancer involves various tests, such as biopsies, MRI, CT scans, & PET scans, to confirm the presence of breast cancer and assess tumor characteristics. These tests are crucial for guiding treatment decisions and gathering essential information about the disease. As the breast cancer diagnostic market becomes increasingly competitive, there is a growing focus on predictive diagnosis.

The prognostic segment is expected to grow at a CAGR of 8.4% over the forecast period. The increasing importance of prognostic tests in matching patients with appropriate therapies has significantly improved survival rates. Companion diagnostics, such as BRACAnalysis CDx by Myriad Genetic Laboratories, Inc.; PD-L1 IHC 22C3 pharmDx by Dako North America, Inc.; and Foundation One CDx by Foundation Medicine, Inc., play a crucial role in this process. Exact Sciences presented novel long-term patient results in multi-cancer early detection and breast cancer recurrence testing at the American Society of Clinical Oncology (ASCO) 2023. The analysis of the SEER program reaffirms the continued confidence in the prognostic value of the Oncotype DX Breast Recurrence Score 3.

End-use Insights

On the basis of end-use, the market is segmented into hospitals & clinics, diagnostics centers & medical laboratories, and others. The hospitals & clinics segment dominated the overall market with a revenue share of 51.00% in 2023 due to the rising number of hospitalizations and increasing burden of breast cancer. These healthcare facilities play a critical role in conducting biopsy procedures after the initial screening tests, while advanced imaging technologies such as PET, CT, & MRI are utilized for effective disease monitoring and treatment evaluation.

Breast Cancer Diagnostics Market Share, By End-use, 2023 (%)

The medical labs & diagnostics centers segment is anticipated to grow at the fastest growth rate over the forecast period with a CAGR of 8.2%. An increase in the number of initiatives undertaken by governments to provide various services, such as reimbursement for diagnostic tests, is expected to boost market growth. Many healthcare institutions are working with laboratories to integrate different tests, such as mammography, ultrasound, and MRI.

Some of the prominent players in the global breast cancer diagnostics market include:

  • Genomic Health (Exact Sciences Corporation)
  • BD
  • Danaher
  • Koninklijke Philips N.V.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Myriad Genetics, Inc.
  • Argon Medical Devices, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hologic Inc.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Breast Cancer Diagnostics market.

By Type 

  • Imaging
  • Biopsy
  • Genomic Tests
  • Blood Tests
  • Others

By Product 

  • Platform-based Products
    • Next-generation Sequencing
    • Microarrays
    • PCR
    • Others
  • Instrument-based Products
    • Imaging
    • Biopsy

By Application 

  • Screening
  • Diagnostic and Predictive
  • Prognostic
  • Research

By End-use 

  • Hospitals & Clinics
  • Diagnostic Centers and Medical Laboratories
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global breast cancer diagnostics market size was estimated at USD 4.49 billion in 2023 and is projected to hit around USD 9.00 billion by 2033

The global breast cancer diagnostics market is expected to grow at a compound annual growth rate of 7.2% from 2024 to 2033

.Based on product, the instrument-based products segment dominated the breast cancer diagnostics market with a share of 72.18% in 2023. This is attributable to the high preference of patients for screening mammography, diagnostic mammography, ultrasonography, and breast MRI.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Breast Cancer Diagnostics Market 

5.1. COVID-19 Landscape: Breast Cancer Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Breast Cancer Diagnostics Market, By Product

8.1. Breast Cancer Diagnostics Market, by Product Type, 2023-2032

8.1.1. Platform-based Products

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Instrument-based Products

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Breast Cancer Diagnostics Market, By Type

9.1. Breast Cancer Diagnostics Market, by Type, 2023-2032

9.1.1. Imaging

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Biopsy

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Genomic Tests

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Blood Tests

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Breast Cancer Diagnostics Market, By Application Type 

10.1. Breast Cancer Diagnostics Market, by Application Type, 2023-2032

10.1.1. Screening

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Diagnostic and Predictive

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Prognostic

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Breast Cancer Diagnostics Market, By End Use Type 

11.1. Breast Cancer Diagnostics Market, by End Use Type, 2023-2032

11.1.1. Hospitals & Clinics

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Diagnostic Centers & Medical Laboratories

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Others

11.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Breast Cancer Diagnostics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2021-2033)

12.1.2. Market Revenue and Forecast, by Type (2021-2033)

12.1.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.1.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Type (2021-2033)

12.1.5.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.1.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Type (2021-2033)

12.1.6.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.1.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.2. Market Revenue and Forecast, by Type (2021-2033)

12.2.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.2.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Type (2021-2033)

12.2.5.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.2.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Type (2021-2033)

12.2.6.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.2.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Type (2021-2033)

12.2.7.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.2.7.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Type (2021-2033)

12.2.8.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.2.8.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.2. Market Revenue and Forecast, by Type (2021-2033)

12.3.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.3.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Type (2021-2033)

12.3.5.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.3.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Type (2021-2033)

12.3.6.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.3.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Type (2021-2033)

12.3.7.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.3.7.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Type (2021-2033)

12.3.8.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.3.8.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.2. Market Revenue and Forecast, by Type (2021-2033)

12.4.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.4.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Type (2021-2033)

12.4.5.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.4.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Type (2021-2033)

12.4.6.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.4.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Type (2021-2033)

12.4.7.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.4.7.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Type (2021-2033)

12.4.8.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.4.8.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.5.2. Market Revenue and Forecast, by Type (2021-2033)

12.5.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Type (2021-2033)

12.5.5.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.5.5.4. Market Revenue and Forecast, by End Use Type (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Type (2021-2033)

12.5.6.3. Market Revenue and Forecast, by Application Type (2021-2033)

12.5.6.4. Market Revenue and Forecast, by End Use Type (2021-2033)

Chapter 13. Company Profiles

13.1. Genomic Health

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. NanoString Technologies Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Paragon Biosciences LLC

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Devicor Medical Products Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. AstraZeneca

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Quest Diagnostics Incorporated

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Koninklijke Philips N.V.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Siemens AG

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Biocept Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Epigenomics Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers